Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. reports developments in AI-enabled personalized spine surgery solutions for lumbar and cervical procedures. The company designs, manufactures and markets the aprevo® technology platform, which combines customized surgical planning with patient-specific implants for spine fusion procedures sold primarily to hospitals and ambulatory surgical centers.
Carlsmed news commonly covers quarterly financial results, revenue guidance, clinical data for aprevo® personalized implants, product updates for cervical and patient-specific fixation systems such as corra™, and management presentations at healthcare and medical technology investor conferences.
Carlsmed (Nasdaq: CARL) announced publication of a retrospective cohort study in Global Spine Journal showing that 3D preoperative planning plus patient-specific aprevo® interbody implants reduced 2-year mechanical-complication revision rates to 4.3% (n=115) versus 16.6% (n=997) with conventional stock implants (p<0.001), a 74% relative reduction. The comparator cohort came from the International Spine Study Group dataset of senior spine surgeons. Authors note improved restoration of distal lumbar lordosis and potential reductions in proximal junctional kyphosis, reoperations, and economic burden. The peer-reviewed article is available online in Global Spine Journal.
Carlsmed (Nasdaq: CARL) announced that Mike Cordonnier, Chairman and CEO, will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 from 4:30–5:10 PM PT in San Francisco.
Carlsmed management also said it will host one-on-one investor meetings during the conference.
Carlsmed (Nasdaq: CARL) announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion on December 3, 2025, and will present early clinical experience at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting, December 3–6, 2025.
The aprevo® Cervical Interbody System pairs AI-driven preoperative planning with 3D-printed, patient-specific implants. Carlsmed reported its first 50+ cervical cases, noting efficient workflow integration, precise implant fit with maximized endplate coverage, and an ability to achieve planned sagittal and coronal alignment versus stock implants.
Carlsmed referenced prior aprevo® lumbar results showing lower complication rates and fewer revision surgeries, cited 370,000 U.S. cervical fusions performed this year as market context, and will hold a CSRS lunch workshop on Dec 4, 2025 at 12:30 PM EST.
Carlsmed (Nasdaq: CARL) announced that Chairman and CEO Mike Cordonnier will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 from 9:00–9:25 AM ET in New York.
Management will host one-on-one investor meetings, a live webcast will be available to registered participants, and a replay will be posted at https://investors.carlsmed.com/.
Carlsmed (Nasdaq: CARL) reported Q3 2025 revenue of $13.1M, a 98% year‑over‑year increase, gross margin of 75.9%, and cash and equivalents of $115.5M as of September 30, 2025. The company raised full‑year 2025 revenue guidance to $49.0–$50.0M (≈80%–84% growth vs. 2024) and shortened aprevo implant lead times to 8 business days. CMS NTAP reimbursement for aprevo cervical procedures took effect Oct 1, 2025; commercial launch expected early 2026 and >50 cervical procedures completed in clinical evaluation. Carlsmed amended its debt facility to increase availability to $50M and extended maturity and interest‑only period.
Carlsmed (Nasdaq: CARL) will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Participants should dial in 5–10 minutes early and can register via the provided participant registration link. A replay of the webcast will be available shortly after the call and will be archived on the company's investor website.
Carlsmed (Nasdaq: CARL), a medical technology company focused on AI-enabled personalized spine surgery solutions, has appointed Jennifer Kamocsay as Chief Legal Officer and Secretary. Kamocsay brings over 20 years of corporate legal experience from companies including Akoya Biosciences, Rubius Therapeutics, and Progress Software Corporation.
The appointment comes as Carlsmed strengthens its leadership team following its IPO and prepares for its cervical commercial launch. Kamocsay's experience spans corporate governance, securities law, and M&A initiatives, with previous roles at prestigious organizations including Skadden, Arps, Slate, Meagher & Flom LLP.
Carlsmed (Nasdaq: CARL) announced its inclusion in the Russell 2000® Index, effective after market close on September 22, 2025. The addition comes following the company's successful IPO in July 2025 and is part of the planned additions of select IPO companies to the index.
The Russell 2000 Index, which tracks the small-cap segment of the U.S. equity market, is widely used by investment managers and institutional investors, with approximately $9 trillion in assets benchmarked against Russell's U.S. indexes. The index represents about 10% of the total market capitalization of the Russell 3000® Index.
Carlsmed (NASDAQ:CARL), a medical technology company specializing in AI-enabled personalized spine surgery solutions, reported strong Q2 2025 financial results. Revenue reached $12.1 million, marking a 99% year-over-year growth. The company achieved a gross margin of 73.4% and reported a net loss of $6.8 million.
Key highlights include the successful completion of their first personalized cervical spine surgery using the aprevo® technology platform, and receiving CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo® cervical procedures. The company maintains a strong financial position with $33.5 million in cash and recently raised $93.5 million through their IPO in July 2025.
Looking ahead, Carlsmed projects full-year 2025 revenue between $45.5-47.5 million, representing 67-75% growth over 2024.
Carlsmed (NASDAQ:CARL) reported strong Q2 2025 financial results, with revenue reaching $12.1 million, representing a remarkable 99% year-over-year growth. The company achieved a gross profit of $8.9 million with a 73.4% gross margin, though experiencing a slight decrease from 75% in Q2 2024.
Despite the revenue growth, Carlsmed reported a net loss of $6.8 million and an Adjusted EBITDA loss of $6.2 million. The company successfully completed its IPO in July 2025, raising $93.5 million in net proceeds. Looking ahead, Carlsmed projects full-year 2025 revenue between $45.5-$47.5 million, indicating 67-75% growth over 2024.
Notable achievements include the completion of their first personalized cervical spine surgery using the aprevo® technology platform and securing CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo® cervical procedures, effective October 2025.